Similarly, TET1 and TET2 genes were upregulated in AML patients [0.0113 (0-3.301) and 0.07 (0–4); respectively] in comparison to the control group [0.001 (0-0.006) and 0.02 (0.008–0.055); respectively], where the significance levels were (P < 0.001 and 0.019; respectively, Fig. 1 A, B, C). The gene discussed is TET2; the disease is acute myeloid leukemia.